NPI: 1871918870 · NORTH PROVIDENCE, RI 02904 · General Acute Care Hospital · NPI assigned 02/27/2014
Authorized official ELDERS, ROBERT controls 20+ related entities in our dataset. Read more
| Authorized Official | ELDERS, ROBERT (SECRETARY) |
| NPI Enumeration Date | 02/27/2014 |
Other providers sharing the same authorized official: ELDERS, ROBERT
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 110,827 | $3.42M |
| 2019 | 123,201 | $5.78M |
| 2020 | 14,341 | $498K |
| 2021 | 11,889 | $310K |
| 2022 | 12,462 | $286K |
| 2023 | 12,641 | $407K |
| 2024 | 8,120 | $230K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99283 | Emergency department visit for the evaluation and management, moderate severity | 3,716 | 2,406 | $804K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 23,108 | 16,630 | $524K |
| 99285 | Emergency department visit for the evaluation and management, high severity with immediate threat to life | 1,390 | 997 | $457K |
| 36415 | Collection of venous blood by venipuncture | 12,061 | 9,671 | $442K |
| 80061 | Lipid panel | 15,068 | 11,256 | $394K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 9,509 | 6,909 | $365K |
| 84443 | Thyroid stimulating hormone (TSH) | 14,377 | 10,297 | $362K |
| 80053 | Comprehensive metabolic panel | 17,118 | 12,389 | $343K |
| 80048 | Basic metabolic panel (calcium, ionized) | 9,198 | 6,877 | $289K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1,123 | 604 | $286K |
| 99213 | Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 4,271 | 3,901 | $284K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 5,260 | 3,354 | $264K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 5,115 | 3,212 | $253K |
| 87660 | 2,142 | 1,417 | $245K | |
| 99284 | Emergency department visit for the evaluation and management, high severity | 1,490 | 1,219 | $242K |
| 81001 | 12,821 | 9,237 | $212K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 4,050 | 2,437 | $153K |
| 83036 | Hemoglobin; glycosylated (A1C) | 9,898 | 7,725 | $149K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1,299 | 858 | $149K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1,096 | 749 | $132K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 978 | 736 | $132K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 8,663 | 6,036 | $125K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1,737 | 455 | $121K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1,252 | 839 | $117K |
| 80076 | 3,329 | 2,533 | $111K | |
| 82962 | 2,297 | 1,147 | $109K | |
| 82607 | 4,841 | 3,720 | $107K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1,636 | 1,215 | $103K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 1,077 | 770 | $99K |
| 71046 | Radiologic examination, chest; 2 views | 1,321 | 964 | $89K |
| 86141 | 1,230 | 894 | $86K | |
| 85027 | 4,110 | 2,715 | $86K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 416 | 285 | $84K |
| 84484 | 1,277 | 762 | $81K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1,020 | 980 | $81K |
| 96375 | Therapeutic injection; each additional sequential IV push | 497 | 353 | $74K |
| 82728 | 3,422 | 2,645 | $74K | |
| 83690 | 1,667 | 1,155 | $71K | |
| 87480 | 2,143 | 1,418 | $64K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 458 | 326 | $64K |
| 83735 | 1,345 | 940 | $61K | |
| 87510 | 2,064 | 1,341 | $61K | |
| 84439 | 4,101 | 3,017 | $60K | |
| 83880 | 507 | 355 | $59K | |
| 86803 | 2,847 | 1,875 | $59K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 987 | 251 | $54K |
| G0378 | Hospital observation service, per hour | 226 | 107 | $54K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 693 | 547 | $53K |
| 84466 | 2,502 | 1,956 | $52K | |
| 80050 | General health panel | 582 | 494 | $52K |
| 87186 | 2,449 | 1,664 | $50K | |
| 85610 | 2,529 | 1,484 | $50K | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 594 | 576 | $49K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 528 | 528 | $48K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 971 | 585 | $47K |
| 82550 | 2,313 | 1,802 | $47K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 418 | 330 | $46K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 498 | 370 | $46K |
| 80074 | 695 | 394 | $45K | |
| J3490 | Unclassified drugs | 608 | 548 | $45K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 494 | 328 | $45K |
| 82565 | 1,202 | 800 | $45K | |
| 82043 | 3,881 | 2,976 | $44K | |
| 87081 | 2,195 | 1,322 | $43K | |
| 83540 | 3,306 | 2,487 | $42K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 432 | 277 | $41K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 398 | 258 | $40K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 540 | 383 | $39K |
| 81025 | 707 | 466 | $36K | |
| 87070 | 1,087 | 785 | $34K | |
| 41899 | Unlisted procedure, dentoalveolar structures | 13 | 13 | $34K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1,346 | 1,132 | $32K |
| 70450 | Computed tomography, head or brain; without contrast material | 300 | 225 | $30K |
| 84520 | 687 | 476 | $30K | |
| 86706 | 1,849 | 1,084 | $30K | |
| 85652 | 3,262 | 2,318 | $30K | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 370 | 362 | $29K |
| 87205 | 902 | 583 | $27K | |
| 82947 | 902 | 588 | $27K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 499 | 328 | $27K |
| 97162 | 293 | 211 | $27K | |
| 82746 | 1,580 | 1,086 | $26K | |
| 87077 | 1,230 | 807 | $26K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 2,725 | 2,139 | $25K |
| 80051 | 522 | 361 | $25K | |
| 86618 | 1,066 | 733 | $25K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 1,895 | 1,792 | $24K |
| 87340 | 1,509 | 900 | $24K | |
| 86900 | 593 | 346 | $24K | |
| 86901 | 593 | 346 | $23K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 110 | 50 | $23K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 94 | 38 | $23K |
| 97597 | 168 | 89 | $22K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 490 | 457 | $22K |
| 86850 | 565 | 334 | $22K | |
| 84154 | 924 | 482 | $22K | |
| 86592 | 2,210 | 1,213 | $20K | |
| 84460 | 2,313 | 1,752 | $19K | |
| 86038 | 1,000 | 674 | $18K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | 1,444 | 781 | $18K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 377 | 126 | $17K |
| 83013 | 201 | 116 | $17K | |
| 88142 | 1,203 | 743 | $16K | |
| 86696 | 608 | 301 | $15K | |
| 85730 | 761 | 548 | $15K | |
| 97035 | 745 | 201 | $14K | |
| 84100 | 341 | 264 | $13K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | 140 | 73 | $13K |
| 84450 | 1,517 | 1,023 | $12K | |
| 86694 | 560 | 269 | $12K | |
| 86695 | 608 | 301 | $12K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 393 | 384 | $11K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 175 | 95 | $11K |
| 86762 | 525 | 285 | $10K | |
| 83605 | 38 | 29 | $10K | |
| 84703 | 346 | 238 | $10K | |
| 84550 | 950 | 699 | $10K | |
| 84480 | 512 | 356 | $9K | |
| J1170 | Injection, hydromorphone, up to 4 mg | 128 | 52 | $9K |
| 84702 | 336 | 198 | $9K | |
| 82150 | 858 | 558 | $9K | |
| 83721 | 373 | 245 | $8K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | 81 | 77 | $8K |
| 86787 | 441 | 233 | $8K | |
| 84403 | 227 | 131 | $7K | |
| 86704 | 407 | 234 | $7K | |
| 84153 | 311 | 217 | $7K | |
| 86765 | 377 | 207 | $7K | |
| 86735 | 373 | 205 | $7K | |
| 84145 | 22 | 12 | $7K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 38 | 27 | $7K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 80 | 77 | $7K |
| J0690 | Injection, cefazolin sodium, 500 mg | 53 | 33 | $7K |
| 86431 | 669 | 427 | $6K | |
| 85379 | 201 | 153 | $6K | |
| 83655 | 830 | 498 | $6K | |
| 82553 | 284 | 174 | $5K | |
| 84436 | 551 | 352 | $5K | |
| 88342 | 82 | 61 | $5K | |
| 82274 | 81 | 79 | $5K | |
| 86780 | 196 | 180 | $5K | |
| 86665 | 201 | 78 | $5K | |
| 84270 | 161 | 95 | $5K | |
| 97167 | 72 | 61 | $5K | |
| 84207 | 146 | 60 | $5K | |
| 84146 | 134 | 80 | $4K | |
| 99214 | Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 48 | 48 | $4K |
| 83516 | 217 | 129 | $4K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 119 | 87 | $4K |
| 84252 | 142 | 55 | $4K | |
| 86617 | 160 | 54 | $3K | |
| 96361 | Intravenous infusion, hydration; each additional hour | 30 | 18 | $3K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 41 | 40 | $3K |
| 86705 | 192 | 80 | $3K | |
| 92551 | 248 | 91 | $3K | |
| 82040 | 363 | 199 | $3K | |
| 84132 | 280 | 171 | $3K | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 33 | 33 | $3K |
| 83970 | 71 | 52 | $3K | |
| 88112 | 17 | 15 | $2K | |
| 73030 | 44 | 32 | $2K | |
| 96127 | 196 | 175 | $2K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 43 | 39 | $2K |
| 85018 | 72 | 42 | $2K | |
| 84425 | 211 | 114 | $2K | |
| 71045 | Radiologic examination, chest; single view | 21 | 14 | $2K |
| 82977 | 201 | 84 | $2K | |
| 86664 | 106 | 78 | $2K | |
| 84481 | 239 | 133 | $2K | |
| 85045 | 305 | 226 | $2K | |
| 72100 | 55 | 29 | $2K | |
| 76642 | 29 | 13 | $2K | |
| S5000 | Prescription drug, generic | 49 | 35 | $2K |
| 86663 | 106 | 78 | $2K | |
| 82465 | 202 | 168 | $2K | |
| 83525 | 93 | 52 | $1K | |
| J2060 | Injection, lorazepam, 2 mg | 21 | 18 | $1K |
| 84402 | 45 | 40 | $1K | |
| 82248 | 80 | 69 | $1K | |
| 97163 | 13 | 12 | $1K | |
| 87430 | 63 | 24 | $1K | |
| 86800 | 53 | 26 | $1K | |
| 86480 | 23 | 12 | $1K | |
| 86677 | 59 | 54 | $1K | |
| 86376 | 50 | 30 | $1K | |
| 83718 | 105 | 93 | $1K | |
| 81002 | 159 | 47 | $1K | |
| 86738 | 71 | 36 | $1K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 19 | 16 | $896.10 |
| 84590 | 53 | 43 | $890.46 | |
| 87522 | Neg quan hep c or qual rna | 18 | 12 | $853.85 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 28 | 12 | $850.60 |
| 85014 | 46 | 25 | $785.84 | |
| 83001 | 30 | 30 | $721.08 | |
| 84075 | 54 | 43 | $670.01 | |
| 80164 | 38 | 28 | $621.02 | |
| 83615 | 18 | 17 | $512.03 | |
| 82670 | 12 | 12 | $428.64 | |
| 83520 | 12 | 12 | $390.81 | |
| 83002 | 16 | 16 | $379.04 | |
| 93000 | 14 | 13 | $358.40 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 22 | 22 | $327.85 |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | 13 | 13 | $234.67 |
| 77063 | Screening digital breast tomosynthesis, bilateral | 12 | 12 | $199.56 |
| 86200 | 12 | 12 | $168.84 | |
| 82270 | 13 | 13 | $27.41 | |
| 90686 | 16 | 13 | $19.24 | |
| J0461 | Injection, atropine sulfate, 0.01 mg | 13 | 13 | $0.00 |